Earnings Report /
Bangladesh

Beximco Pharmaceuticals: FY21 – Annual NPAT posted c46% yoy growth

  • EPS of the company stood at BDT 11.5 (NPAT BDT 5,126mn) in FY21, implying c46% growth

  • Q4 FY21 EPS stood at BDT 3.26 against BDT 1.99

  • BXPHAR declared BDT 3.5/share cash dividend

Shopnil Paul
Shopnil Paul

Research Associate

Follow
IDLC Securities
25 October 2021
Published byIDLC Securities
  • EPS of the company stood at BDT 11.5 (NPAT BDT 5,126mn) in FY21, implying c46% growth over BDT 7.9 (NPAT BDT 3,515mn) in FY20.

  • Q4 FY21 EPS stood at BDT 3.26 against BDT 1.99 in Q4 FY20, thus implying c64% earnings growth yoy.

  • BXPHAR declared BDT 3.5/share cash dividend (c30% pay-out) in FY21 against BDT 1.4/share cash dividend (c17% pay-out) in FY20. The dividend declaration for FY21 outperformed our expectation by c75%.